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Lysosomal acid lipase (LAL) deficiency is an autosomal recessive lysosomal storage disorder caused by mutations in the LIPA gene
that leads to premature organ damage and mortality. We present retrospective data from medical records of 5 Brazilian patients,
showing the broad clinical spectrum of the disease.
1. Introduction
Lysosomal acid lipase (LAL) deficiency (cholesteryl ester
storage disease/Wolman disease; Online Mendelian Inher-
itance in Man database #278000) is an autosomal recessive
lysosomal storage disorder caused by mutations in the LIPA
gene that reduce LAL activity [1].
Deficient activity of LAL leads to the accumulation of
cholesteryl esters and triglycerides in most tissues, dem-
onstrating the enzyme’s role in cholesterol and triglyceride
metabolism. LAL deficiency leads to a poorly defined
continuum of symptoms, historically divided into Wolman
disease (early onset), first described in 1956 [2], and cho-
lesteryl ester storage disease (late onset) [1, 3], first described
in 1963 [4].
LAL deficiency presenting in infants is a neonatal-onset,
severe, and lethal form, resulting in severely affected lyso-
somes, due to accumulation of cholesteryl esters and tri-
glycerides, predominantly in the liver, spleen, gut, adrenal
glands, bone marrow, lymph nodes, and macrophages.
Affected infants present at an early age, with vomiting,
diarrhea, and massive hepatosplenomegaly. Feeding diffi-
culties and malabsorption lead to malnutrition, growth
retardation, and cachexia, which, together with the severe
liver disease, contribute to the patient’s early demise, gen-
erally in the first year of life [5, 6].
In other cases, LAL deficiency may present in any period
of life; some patients are diagnosed in childhood, while
others remain undiagnosed until adulthood [7]. 'e pro-
gressive accumulation of lysosomal cholesteryl esters and
triglycerides leads to the characteristic liver disease, elevated
serum transaminase levels, and elevated serum low-density
lipoprotein cholesterol (LDL-C) concentrations, with nor-
mal to low high-density lipoprotein cholesterol (HDL-C)
concentrations. Premature demise is due to liver failure
and/or accelerated atherosclerotic disease secondary to the
chronic hyperlipidemia [1, 2, 7].
Liver biopsies may not be pathognomonic for LAL
deficiency, which may be misdiagnosed as nonalcoholic fatty
liver disease, nonalcoholic steatohepatitis, or cryptogenic
cirrhosis. Despite being an excellent exam for diagnosis and
also for evaluating the degree of liver compromise, it is an
invasive exam, with potential risk of complications such as
hemorrhage, specially in patients with advanced liver disease
[8]. Another important tool to help elucidate the diagnosis is
the endoscopy, which can present specific findings such as
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disseminated lipidic accumulation or other nonspecific signs,
such as aesophagus varices [9]. Diagnostic suspicion can also
be confirmed by demonstrating the deficient LAL activity via
biochemical tests (i.e., dried blood spot, leukocytes, and fi-
broblasts) and determination of mutations on the LIPA gene
by performing gene sequencing, which can help identify
patients with this autosomal recessive disease without po-
tential complications [10]. To date, the genotype-phenotype
correlation has not been established.
In 2013, Bernstein et al. [11] reviewed 135 cases of LAL
deficiency in the literature, showing the clinical variability
of the disease. Despite the variability, the majority of cases
were recognized in infancy, early childhood, or adolescence
(83% of cases presented with the first clinical manifestation
prior to 12 years of age), showing the important role of the
pediatrician in early detection of clinical symptoms.
In this study, we report the clinical, biochemical, and
histological aspects observed across the age spectrum: 1 case
in infancy and 4 pediatric cases in siblings.
2. Methods
2.1. Patients. 'is is a retrospective study reviewing data from
medical records of patients from a Brazilian Reference Center
for Inborn Errors of Metabolism, Universidade Federal de São
Paulo (Institutional Review Board/Ethics Committee approval
number CEP-UNIFESP 2007/11).
2.2. Biochemical Diagnosis. LAL enzymatic activity assay
was performed in dried blood spot (DBS) samples according
to the fluorimetric technique described by Hamilton et al.
[12] and performed at HRG Laboratory, HIBM Research
Group (Chatsworth, CA, USA), which used the reference
range of 0.37–2.30 nmol/punch/h. Biochemical analysis was
also performed in our laboratory—Laboratório de Erros
Inatos do Metabolismo (LEIM)–UNIFESP, which used the
reference range of >0.024 nmol/punch/h.
2.3. Pathology. All patients underwent ultrasound-guided
liver biopsy in order to evaluate liver damage. PAS-D stain
(periodic acid-Schiff + diastasis) was performed to differ-
entiate lipid from glycogen deposit, and Masson trichrome
was performed to evaluate presence of cirrhosis.
3. Results
3.1. Case 1. 'e patient is a female, index case of this family,
second of five siblings from the same mother, who has a son
(unaffected) and a daughter (this patient) from her first
marriage, and three other sons (all affected—cases 2, 3,
and 4), from her second marriage. Both marriages were
nonconsanguineous unions, and both fathers are not related.
'e mother of cases 1, 2, 3, and 4 also has reduced activity of
LAL enzyme, but her case was not presented in this report.
Onset of symptoms occurred at 3 years of age; she was
referred to a gastroenterologist for hepatomegaly, in-
termittent diarrhea, and failure to thrive. She underwent
liver biopsy at 3 years of age, showing granulomatous
hepatitis with generalized hepatocellular stuffing. Grade 3
macro- and microvesicular diffuse steatosis was present in 60%
of the hepatocytes. 'e patient was first evaluated in our service
at the age of 4 years; she weighed 16 kg (z score of −0.56),
her height was 93 cm (z score of −3.0), and she had hep-
atosplenomegaly (rounded liver with rock-hard consis-
tency, 5 cm below the right costal margin; rock-hard
consistency spleen, 5 cm below the left costal margin). Her
second hepatic biopsy showed enlargement of portal spaces
with enlarged microvacuolized macrophages and hepatocytes.
She developed progressive increase of hepatosplenomegaly—by
age 9, physical examination revealed that her liver was 20 cm
below the right costal margin and her spleen was 17 cm below
the left costal margin—and worsening of diarrheic episodes.
Biochemical analysis showed dyslipidemia and mild ele-
vation of liver transaminases (Table 1). Between 8 and 9
years of age, she underwent 7 hospitalizations due to re-
spiratory distress secondary to severe hepatosplenomegaly.
'e patient died at age 9, due to pneumonia and septic
shock; at that time, the enzymatic assay was not available in
our country, and thus her diagnosis was confirmed by en-
zymatic assay in DBS samples postmortem showing LAL
activity to be 0.0068 nmol/punch/h (reference range, 0.37–
2.30 nmol/punch/h). 'e autopsy showed disseminated lipid
and cholesterol crystal accumulation, mainly in the liver,
spleen, bone marrow, and gastrointestinal tract, and severe
steatosis with lipid-filled histiocytes (Figure 1). No adrenal
calcification was noted.
3.2. Case 2. 'e patient is a male, half-brother of the patient
in case 1, currently 11 years old, onset of symptoms at age 3,
presenting with hepatosplenomegaly. In his first evaluation
at our center at 4 years of age, clinical examination showed
enlarged abdominal circumference, round liver 5 cm below
the right costal margin, spleen 3 cm below the left costal
margin, and growth deficit, weighing 15 kg (z score of −1)
and measuring 96 cm (z score of −2.4) with a body mass
index (BMI) of 16.5 (z score of 0.92). Laboratory assessment
showed elevation in total cholesterol, with a low HDL-C
level and high LDL-C level. His triglyceride level was ele-
vated, with slight increase in liver enzymes (Table 1). Hepatic
biopsy presented hepatocyte dilatation due to lipid ac-
cumulation, lipid-filled histiocytes, and broadening portal
spaces suggesting lipid storage disease (Figure 1). Enzy-
matic assay in DBS samples showed LAL activity to be
0.0087 nmol/punch/h (reference range, 0.37–2.30 nmol/
punch/h), confirming the diagnosis.
3.3.Case3. 'e patient is a male, younger half-brother of the
patient in case 1, currently 10 years old, diagnosed at the age
of 6 years in the familial screening. In his first evaluation, at
6 years old, no hepatosplenomegaly and no growth delay
were noticed, with the patient weighing 20 kg (z score
of −0.46) and measuring 114 cm (z score of −0.77), with
a BMI of 15.4 kg/m2 (z score of 0.03). Laboratory assessment
showed mild elevation of total cholesterol and the LDL-C
fraction, and a low HDL-C fraction. Triglycerides were
also mildly elevated (Table 1), but transaminase levels
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were normal. Abdominal sonogram showed discrete homo-
geneous hepatomegaly for the patient’s age. Enzymatic assay
of DBS samples showed LAL activity to be 0.00 nmol/punch/h
(reference range, >0.024nmol/punch/h), confirming the
diagnosis.
3.4. Case 4. 'e patient is a male, younger half-brother of
the patient in case 1 currently 8 years old, who was di-
agnosed at the age of 3 years in the familial screening. In his
first assessment in our service, at the age of 2 years and 11
months, the patient presented with sporadic episodes of
Table 1: Laboratory assessment of patients at the time of diagnosis.
Patient 1a Patient 2 Patient 3 Patient 4 Patient 5 Reference range
AST (U/L) 55 80 35 39 909 <40
ALT (U/L) 35 76 30 38 1449 <41
GGT (U/L) 17 19 19 17 754 ≤60
Alkaline phosphatase (U/L) 194 140 243 221 668 <390
Total cholesterol (mg/dL) 212 222 177 164 287 <170
HDL-C (mg/dL) 12 19 34 31 28 >39
LDL-C (mg/dL) 148.8 170 146 117 234 <110
VLDL-C (mg/dL) 51.2 33 — — 25 —
Triglycerides (mg/dL) 256 167 108 111 125 <100
Total bilirubin (mg/dL) 4.04 0.5 0.39 0.7 16.08 <1
DB (mg/dL) 3.2 0.2 0.13 0.2 12.64 0.0–0.2
IB (mg/dL) 0.84 0.3 0.26 0.5 3.44 0.1–0.6
ALT, alanine aminotransferase; AST, aspartate aminotransferase; DB, direct bilirubin; GGT, gamma-glutamyltransferase; HDL-C, high-density lipoprotein
cholesterol; IB, indirect bilirubin; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very-low-density lipoprotein cholesterol. aSamples were collected by
the time the clinical diagnosis of LALD was suspected, since the biochemical diagnosis was established postmortem.
(a) (b)
(c) (d)
Figure 1: (a) Liver autopsy of case 1 showing disseminated lipid accumulation and severe steatosis with lipid-filled histiocytes (arrows)
(Masson trichrome stain, 10x). (b) Duodenum biopsy of case 1 showing deformed villus, justifying the diagnosis of malabsorption
syndrome. Lamina propria showing PAS+, diastasis-resistant material (arrows) (PAS+ diastase stain, 20x). (c) Liver biopsy of case 2 showing
lipid-filled histiocytes and broadening portal spaces (arrows) (Masson trichrome stain, 10x). (d) Liver biopsy of case 5 showing severe
macro- and microvesicular steatosis (arrows) (hematoxylin and eosin stain, 10x).
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diarrhea. No hepatomegaly and no growth delay were
noticed; the patient weighed 16 kg (z score of 0.9) and
measured 95.5 cm (z score of −0.35), with a BMI of
17.8 kg/m2 (z score of 1.63). Laboratory assessment showed
that his total cholesterol level was within the normal range,
but he had mildly low HDL-C and mildly high LDL-C levels.
Triglycerides were also elevated (Table 1). Abdominal sono-
gram showed that the liver and spleen were within the upper
limit of normal for the patient’s age. Enzymatic assay of
DBS samples showed LAL activity to be 0.00 nmol/
punch/h (reference range, >0.024 nmol/punch/h), confirm-
ing the diagnosis.
3.5. Case 5. 'e patient is a male, not related to the previous
patients, with neonatal cholestasis until 20 days of life. He
was first evaluated at our center in 2012 at 4 months of age
with a perinatal history of cholestasis and hypoglycemia;
severe jaundice (Kramer scale score of 5); severe hep-
atosplenomegaly (liver and spleen 5 cm below the costal
margin); failure to thrive, weighing 5150 g (z score of −2.51)
and measuring 60.5 cm (z score of −1.43), with a BMI of 14.1
(z score of −2.35); blood dyscrasia; impaired liver function,
with severe hepatic and canalicular enzyme level elevations;
and very high total cholesterol, low HDL-C, and high LDL-C
levels. Triglycerides were also elevated (Table 1). 'e patient
presented with severe pancytopenia and hemophagocytic
lymphohistiocytosis syndrome. By the age of 8 months, the
patient underwent liver transplantation due to hepatic
failure and died soon after the procedure due to acute organ
rejection. Liver biopsy showed severe macro- and micro-
vesicular steatosis with associated severe fibrosis and portal
ductular reaction (Figure 1). 'e DBS samples showed LAL
activity to be 0.0324 nmol/punch/h (reference range, 0.37–
2.30 nmol/punch/h). LIPA gene sequencing presented two
heterozygous mutations: an exon 5 deletion (c.477delT) and
an exon 7 insertion (c.822+37_38insC).
4. Discussion
Clinically, LAL deficiency, like other lysosomal storage
disorders, can present across the age spectrum. It is often
unrecognized in infants as well as in children and adults.
In children and adults, once a physician notes the hepa-
tomegaly, with or without splenomegaly and/or elevated
transaminase activity, suspicion for LAL deficiency in-
creases, but this first requires an awareness of the disease
[4]. Typically, a liver biopsy will reveal foamy, lipid-filled
hepatocytes and macrophages, microvesicular steatosis,
and lysosomal cholesteryl ester crystals, best observed by
ultrastructural examination [13].
'e hepatosplenomegaly in cases 1 and 2 was noticed
by 3 years of age; this finding can be an alert to pedia-
tricians and hepatologists, once frequent causes of he-
patomegaly are discarded, with or without splenomegaly,
as reported by Bernstein et al. [11] in 2013, after analyzing
135 cases of LAL deficiency found that 99,3% of the patients
presented hepatomegaly and 74% presented splenomegaly,
being those the most frequent first signs of the disease. In
contrast, the patient in case 3 did not have evidence of he-
patomegaly at age 6, demonstrating the variety of the clinical
spectrum, even between siblings, who are supposed to carry
the same mutation. On the other hand, the patient in case
5 presented at an early age with severe hepatosplenomegaly
and early-onset hepatic failure. When compared to the other
cases, the patient in case 5 presented a much more severe and
much more early-onset symptoms, showing the clinical
variability of this disease.
Regarding the dyslipidemia, four out of five patients
showed abnormal levels of total cholesterol, and all pa-
tients showed abnormal cholesterol fractions and tri-
glycerides, being higher on the patient with an early-onset
“Wolman” phenotype. In children and adults with LAL
deficiency, laboratory parameters of cholesterol are not
always severely abnormal, as reported by Bernstein et al. in
2013, when reviewing 135 cases of patients with LAL
deficiency, where 79% of the patients presented total
cholesterol > 200 and 71% had HDL-C between 20 and 40
[11]. As previously reported, patients with higher levels of
total cholesterol and LDL-C do not necessarily present
with more severe lipid deposits and impaired liver func-
tion than patients with lower levels [7].
Regarding liver enzymes, we can observe that patients 1
to 4 had moderately increased aspartate aminotransferase,
alanine aminotransferase, gamma-glutamyltransferase, and
alkaline phosphatase levels, and patient 5 showed much
more severe compromise of liver function, with much higher
enzyme levels.
'e liver biopsies of the patients in cases 1 and 2 show
us disseminated lipid accumulation and severe steatosis
with lipid-filled histiocytes, marking the important lipid
deposits in hepatocytes, leading to cellular damage and
subsequent organic failure. In case 5, we can see more
important tissue damage, with severe macro- and micro-
vesicular steatosis and fibrosis presenting at an early stage.
'at follows the pattern showed in the literature so far
[14, 15] and, despite the initial presenting symptoms or
signs, the presence of dyslipidemia, hypertriglyceridemia,
and increased liver enzyme levels must lead to the suspicion
of LAL deficiency.
'ese cases in addition to the published literature
[1, 16–18] show the broad clinical spectrum of this disease
and highlight the importance of health care professionals
having LAL deficiency in mind as a potential diagnosis when
evaluating a patient with hepatomegaly with or without
splenomegaly, elevated liver enzymes, dyslipidemia, and/or
growth abnormalities, because the early identification of
patients is an important prerequisite for timely treatment
with enzyme replacement therapy [19].
5. Conclusion
LAL deficiency should be included in the differential di-
agnosis for all patients with elevated LDL-C who also may
have mildly to moderately decreased HDL-C levels, elevated
transaminases, and hepatomegaly. Enzyme replacement
therapy with sebelipase alfa is an option in some areas of the
world. 'us, the early detection of patients is advised,
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because the earlier the patient starts the treatment, the better
the outcome will probably be.
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